KR20090087094A - Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물 - Google Patents

Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물 Download PDF

Info

Publication number
KR20090087094A
KR20090087094A KR1020097013350A KR20097013350A KR20090087094A KR 20090087094 A KR20090087094 A KR 20090087094A KR 1020097013350 A KR1020097013350 A KR 1020097013350A KR 20097013350 A KR20097013350 A KR 20097013350A KR 20090087094 A KR20090087094 A KR 20090087094A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
substituted
cycloalkyl
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020097013350A
Other languages
English (en)
Korean (ko)
Inventor
제임스 더글라스 그리핀
레이 자웰
Original Assignee
노파르티스 아게
다나-파버 캔서 인스티튜트 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 다나-파버 캔서 인스티튜트 인크. filed Critical 노파르티스 아게
Publication of KR20090087094A publication Critical patent/KR20090087094A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097013350A 2006-11-28 2007-11-27 Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물 Abandoned KR20090087094A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US60/867,448 2006-11-28
US89108807P 2007-02-22 2007-02-22
US60/891,088 2007-02-22

Publications (1)

Publication Number Publication Date
KR20090087094A true KR20090087094A (ko) 2009-08-14

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097013350A Abandoned KR20090087094A (ko) 2006-11-28 2007-11-27 Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물

Country Status (20)

Country Link
US (1) US8492429B2 (https=)
EP (1) EP2089024B1 (https=)
JP (1) JP5394249B2 (https=)
KR (1) KR20090087094A (https=)
AT (1) ATE509629T1 (https=)
AU (1) AU2007325280B2 (https=)
BR (1) BRPI0719543A2 (https=)
CA (1) CA2670498A1 (https=)
CO (1) CO6210722A2 (https=)
EC (1) ECSP099472A (https=)
GT (1) GT200900142A (https=)
IL (1) IL198551A0 (https=)
MA (1) MA30966B1 (https=)
MX (1) MX2009005621A (https=)
NO (1) NO20092417L (https=)
PL (1) PL2089024T3 (https=)
PT (1) PT2089024E (https=)
RU (1) RU2456983C2 (https=)
TN (1) TN2009000206A1 (https=)
WO (1) WO2008067280A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020171646A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
US12325698B2 (en) 2018-07-25 2025-06-10 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US9750729B2 (en) * 2008-05-16 2017-09-05 Dana-Farber Cancer Institute, Inc. Immunomodulation by IAP inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
CA2850330A1 (en) 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
RS52545B (sr) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
WO2007075525A2 (en) * 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
PE20110220A1 (es) * 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12325698B2 (en) 2018-07-25 2025-06-10 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
WO2020171646A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
US12433867B2 (en) 2019-02-22 2025-10-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents

Also Published As

Publication number Publication date
MX2009005621A (es) 2009-06-12
RU2009124590A (ru) 2011-01-10
PL2089024T3 (pl) 2011-10-31
US8492429B2 (en) 2013-07-23
JP2010511059A (ja) 2010-04-08
AU2007325280B2 (en) 2011-03-10
BRPI0719543A2 (pt) 2014-02-25
AU2007325280A1 (en) 2008-06-05
JP5394249B2 (ja) 2014-01-22
ECSP099472A (es) 2009-10-30
WO2008067280A3 (en) 2008-08-07
PT2089024E (pt) 2011-08-31
CO6210722A2 (es) 2010-10-20
RU2456983C2 (ru) 2012-07-27
EP2089024A2 (en) 2009-08-19
NO20092417L (no) 2009-08-25
TN2009000206A1 (en) 2010-10-18
WO2008067280A2 (en) 2008-06-05
GT200900142A (es) 2010-06-24
IL198551A0 (en) 2010-02-17
US20100056467A1 (en) 2010-03-04
CA2670498A1 (en) 2008-06-05
MA30966B1 (fr) 2009-12-01
EP2089024B1 (en) 2011-05-18
ATE509629T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
KR20090087094A (ko) Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물
KR20090083412A (ko) 급성 골수성 백혈병의 치료를 위한 ｉａｐ 억제제의 용도
CA2889717A1 (en) Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
JP7577672B2 (ja) Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
KR20070074552A (ko) 포스포디에스테라아제 ５ 억제제（ｐｄｅ５）와 조합한엔도텔린 ａ 수용체 （ｅｔａ）길항제 및 이의 용도
JP2007530705A (ja) トリシリビン及び関連化合物による、腫瘍及び癌の有効な治療
KR20210003789A (ko) 림프종을 치료하는 방법
WO2017037587A1 (en) Combination of ribociclib and dabrafenib for treating or preventing cancer
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
EP1638574B1 (en) New pharmaceutical uses of staurosporine derivatives
KR20080018947A (ko) Ｆｌｔ3 억제제 및 파네실 트랜스퍼라제 억제제를 사용한ｆｌｔ3 키나아제의 상승적 조절
CN119403808A (zh) 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂
WO2022094435A1 (en) Modulators of orphan nuclear receptors for treating pancreatitis, glioblastoma, sarcopenia and stroke
WO2012078416A2 (en) Monophosphate prodrugs of dapd and analogs thereof
KR20080038298A (ko) 아미노피리미딘 조절제 및 파네실 전이 효소 억제제를이용하는 ｆｌｔ３ 키나아제의 상승적 조절
KR20080038297A (ko) 아미노피리미딘 키나아제 조절제를 사용한 ｆｌｔ3키나아제의 상승적 조절
CN113490497A (zh) 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
EP2249844A1 (en) Active substance combination with gemcitabine for the treatment of epithelial cancer
von Mehren New therapeutic strategies for soft tissue sarcomas
CN101588801B (zh) Iap抑制剂和flt3抑制剂的组合
ES2549327T3 (es) Derivados de pirimidilaminobenzamida para el tratamiento de la neurofibromatosis
AU2005279344B2 (en) Use of midostaurin for treating gastrointestinal stromal tumors
WO2025012029A1 (en) Therapeutic combination comprising 4-(4-methyl-piperazin-1-yl)-n-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1h-indazol-3-yl}-benzamide and an antineoplastic agent
HK40111044A (zh) 用於治疗急性髓系白血病的flt3抑制剂和bcl-2抑制剂的治疗有效组合
Ghias 8-Amino-adenosine and induction of apoptosis in multiple myeloma: Effect of novel purine analog on cellular signaling pathways

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131231

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20141126

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee